Describing late Ajit Pawar as ’the best Chief Minister Maharashtra never had,’ Chief Minister Devendra Fadnavis paid an ...

It's entirely possible that Pfizer stock will indeed rebound this year. Perhaps the most likely reason for a bounce is the potential for positive clinical results that excite investors. Many will ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions. Revenue in 2026 will be $59.5 ...

Pfizer Inc. (NYSE: PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.

Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...

Deal marks Pfizer's re-entry into obesity treatment market Pfizer shares rise 1.4%, Novo Nordisk falls 1.3% Metsera candidate MET-097i advances to late-stage trials The greenlight from Metsera's ...

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer’s Internal Medicine portfolio Positions ...

Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy. By Francesca Regalado The obesity drug developer ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...